Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993;32(2):151-5.
doi: 10.1007/BF00685619.

Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines

Affiliations

Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines

E Roller et al. Cancer Chemother Pharmacol. 1993.

Abstract

Modulators for the reversal of multidrug resistance such as R-verapamil and B8509-035, a dihydropyridine, effectively overcome multidrug resistance in vitro and are currently undergoing clinical trial. One problem with their use is the application protocol; the question as to whether they should be given by continuous administration or in sequential doses in combination with the cytotoxic drugs has to be addressed. Therefore, we examined the influence of the exposure time and the sequence of modulator administration on the active transport of the fluorescent dye rhodamine 123 (R123), a substrate for the P-glycoprotein, in the resistant lymphoblastoid cell line VCR1000 and the parental nonresistant cell line CCRF-CEM. Our results demonstrate the importance of coadministration of R-verapamil and the cytotoxic agent for the modulation of multidrug resistance, whereas the exposure sequence does not seem to be such an essential parameter in the case of B8509-035. This observation should be considered for the further design of clinical studies.

PubMed Disclaimer

References

    1. J Biol Chem. 1987 Jun 5;262(16):7884-8 - PubMed
    1. Cancer Res. 1989 Nov 1;49(21):5798-804 - PubMed
    1. Cancer Res. 1983 Jun;43(6):2905-10 - PubMed
    1. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7785-9 - PubMed
    1. Biochem Pharmacol. 1989 Dec 1;38(23 ):4267-71 - PubMed

Publication types

MeSH terms